What Is Calcitonin? Benefits, Research & Safety
A thyroid hormone involved in calcium regulation, used therapeutically for osteoporosis, Paget's disease, and hypercalcemia.
UK summary: UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.
Quick Facts
Overview
Calcitonin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Available for specific indications; use restricted to short-term treatment.
- EU: Use restricted due to cancer risk concerns; limited indications.
- Notes: Calcitonin use has been restricted in many jurisdictions following EMA recommendations in 2013. Long-term use for osteoporosis is no longer recommended. Short-term use for hypercalcemia and Paget's disease remains appropriate.
05Approved medical uses
- Hypercalcaemia (acute / cancer-related — Miacalcic IV).
- Paget's disease of bone (short-term).
- Acute vertebral fracture pain (nasal calcitonin — limited modern use).
06Unapproved / promotional claims
- Calcitonin as first-line long-term osteoporosis treatment.
- Daily calcitonin nasal spray for healthy adults.
07Common internet claims
- Some online sources still promote calcitonin for osteoporosis prevention despite restricted indication.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Best long-term option for osteoporosis” | B | Yes | High | Calcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- EMA / MHRA cancer-risk signal restricted long-term osteoporosis use (2013).
- Nasal irritation, flushing.
- Antibody formation with chronic use.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Available for specific indications; use restricted to short-term treatment.
14EU legal position
Use restricted due to cancer risk concerns; limited indications.
15What this page cannot tell you
- Whether off-label long-term use carries the same cancer signal as restricted indication.
16Last reviewed
17Citation quality score
18Research gaps
- Superseded by bisphosphonates / denosumab / teriparatide for routine osteoporosis.
19Safer alternatives / established care pathways
- NICE TA161 / TA204 osteoporosis pathway: lifestyle + calcium / vitamin D + bisphosphonate first-line.
- Specialist referral for severe / refractory cases.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the appropriate UK osteoporosis treatment for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Rapid reduction of hypercalcemia
- 2Reduction of bone turnover in Paget's disease
- 3Pain relief in vertebral fractures and bone disease
- 4Modest reduction in vertebral fracture risk (osteoporosis)
- 5Important tumor marker for medullary thyroid cancer
Claim vs Evidence
How popular claims about Calcitonin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Best long-term option for osteoporosis” | B | Yes | High | Calcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Varies by indication; 200 IU nasal daily for osteoporosis; 4-8 IU/kg injection for hypercalcemia |
| Frequency | Daily (nasal) or as needed (injection) |
| Duration | Limited duration recommended due to cancer concerns |
| Notes | Calcitonin use has declined due to availability of better alternatives and cancer risk concerns. It remains useful for specific situations like acute hypercalcemia and Paget's disease. Use should be time-limited. |
Administration Routes
Routes studied in research settings (educational only):
- Nasal spray (osteoporosis, most convenient)
- Subcutaneous or intramuscular injection
- Intravenous (hypercalcemia emergencies)
| Half-Life | Stability |
|---|---|
| Approximately 10-15 minutes (short) | Commercial preparations stable per manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nasal irritation and rhinitis (nasal spray)
- Nausea
- Flushing
- Injection site reactions
- Allergic reactions (especially salmon-derived)
Rare Risks & Concerns
- Increased cancer risk with long-term use
- Serious allergic/anaphylactic reactions
- Hypocalcemia (excessive effect)
Contraindications
- Known hypersensitivity to calcitonin
- Hypocalcemia
- Long-term use discouraged
UK & EU Regulatory Context
🇬🇧 United Kingdom
Available for specific indications; use restricted to short-term treatment.
🇪🇺 European Union
Use restricted due to cancer risk concerns; limited indications.
Clinical Studies Summary
Calcitonin for Osteoporosis
Clinical trials showing modest reduction in vertebral fractures with nasal calcitonin.
Calcitonin as Tumor Marker in MTC
Calcitonin measurement for diagnosis and monitoring of medullary thyroid cancer.
Looking for Calcitonin?
Source research-grade Calcitonin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Calcitonin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the appropriate UK osteoporosis treatment for my situation?
UK regulatory & safety context
Related Peptides
ACTH
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn morePTH 1-34
The biologically active fragment of parathyroid hormone approved for osteoporosis treatment, representing the first anabolic bone therapy.
Learn more